Normal subjects | SARS patients | ||
---|---|---|---|
60 days | 90 days | ||
(n = 9) | (n = 12) | (n = 6) | |
Lymphocytes (103 cells/ml) | 5.8 ± 1.4 | 39.2 ± 12.1* | 9.7 ± 2.4† |
CD3 cells (%) | 39.7 ± 6.4 | 33.1 ± 6.7 | 37.8 ± 6.1 |
CD3 cells (103 cells/ml) | 2.4 ± 0.5 | 16.3 ± 6.4* | 3.3 ± 0.7 |
CD4 cells (%) | 9.2 ± 2.6 | 8.7 ± 2.2 | 10.4 ± 4.3 |
CD4 cells (103 cells/ml) | 1.2 ± 0.3 | 4.4 ± 2.0* | 0.8 ± 0.3 |
CD8 cells (%) | 6.6 ± 2.6 | 20.1 ± 5.5* | 13.2 ± 3.3 |
CD8 cells (103 cells/ml) | 0.7 ± 0.1 | 11.8 ± 4.7* | 1.1 ± 0.2† |
CD4/CD8 (ratio) | 1.89 ± 0.22 | 0.62 ± 0.12* | 0.73 ± 0.12† |
B cells (%) | 6.7 ± 1.2 | 3.2 ± 0.8 | 2.8 ± 0.6 |
B cells (103 cells/ml) | 0.4 ± 0.1 | 1.4 ± 0.7 | 0.3 ± 0.1 |
NK cells (%) | 1.8 ± 0.2 | 8.8 ± 2.6* | 5.8 ± 2.1 |
NK cells (103 cells/ml) | 0.1 ± 0.03 | 4.0 ± 2.4** | 0.3 ± 0.1† |